What was the primary endpoint evaluated in relation to early patient-reported symptoms in this I-SPY2 analysis?
Pathologic complete response (pCR) in patients receiving immunotherapy or ADC-based neoadjuvant therapy
Overall survival in patients with high-risk early breast cancer
Treatment discontinuation rates due to adverse events